Trials / Approved For Marketing
Approved For MarketingNCT00438789
The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The primary objective is to provide access to eculizumab for PNH patient pending commercial availability.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | eculizumab | 600mg IV every week and 900mg IV every 2 weeks |
Timeline
- First posted
- 2007-02-22
- Last updated
- 2014-05-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00438789. Inclusion in this directory is not an endorsement.